Enzalutamide resistance in C42-B prostate cancer cells

ABSTRACT: Castration resistant prostate cancer (CRPC) develops resistance to antiandrogens affecting Androgen Receptor (AR) signaling through a variety of mechanism. Because of this, the efficacy of androgen receptor targeted therapy remains limited for many patients with CRPC. We developed C42B-enzalutamide (ENZU) and resistance cells to study changes in transcriptomic profile compared to parental cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE151083 | GEO | 2020/12/31

REPOSITORIES: GEO